Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Prova di calore (terapia anticorpale HER2 con lutetium-177) (RAD202)

21 settembre 2026 aggiornato da: Radiopharm Theranostics, Ltd

Fase 0/1 Studio sulla sicurezza e la tollerabilità di 177LU-RAD202, un anticorpo a dominio singolo radiomarico di lutetium-177 contro il recettore 2 del fattore di crescita epidermico umano in pazienti con tumori solidi avanzati

This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a first-in-human, Phase 0/1, open-label study of 177Lu-RAD202 consisting of a Screening Period, a Treatment Period with 177Lu-RAD202 and a Safety and Long-Term Follow-Up Period to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

Screening Period: Screening period of up to 4 weeks Phase I (Treatment Period): 177Lu-RAD202 dose escalation

  • Treatment Period with each cycle lasting 6 weeks. Extension of the planned dose intervals are possible following discussion and agreement between the Sponsor and Investigator.
  • Participants may be treated with multiple cycles as long as they appear to derive clinical benefit as determined by the Investigator and provided adequate clinical safety and organ dosimetry data.
  • DLT observation period for 177Lu-RAD202 is 6 weeks following first injection of 177Lu-RAD202.
  • Should an alternative treatment schedule be explored, the DLT observation period for 177Lu-RAD202 at that dose level will be the proposed cycle duration.

Safety Follow-Up Period:

  • An End of Treatment Visit performed within 7 days of the last dose of 177Lu-RAD202
  • A Safety Follow-up Visit performed every 12 ± 2 weeks from the End of Treatment Visit

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Prima fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • New South Wales
      • Kingswood, New South Wales, Australia, 2747
      • Macquarie Park, New South Wales, Australia, 2109
      • Wollongong, New South Wales, Australia, 2500
    • Victoria
      • Fitzroy, Victoria, Australia, 3065
        • Reclutamento
        • St Vincents Hospital, Melbourne
        • Contatto:
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Aged 18 years and older.

  2. Written, voluntary, informed consent of the participants must be obtained in compliance with institutional, regional, and federal guidelines.

  3. Participants with histologically or cytologically confirmed, HER2 positive or HER2-low, advanced solid tumours that are relapsed/refractory, locally advanced not amenable to curative-intent therapy, or metastatic, with documented disease progression during or after their most recent line of anti-cancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit.

    Participant HER2 positivity is determined by local testing and is defined as a score of 3+ on immunohistochemical analysis IHC), or, defined as a score of 2+ on IHC and positive results on in situ hybridisation (ISH). HER2-low is defined as a score of 1+ on IHC analysis or a score of 2+ on IHC analysis with ISH negative. If the participant tumor's HER2 status is unknown, it may be determined in a pre-screening step whereby the participant is asked to provide written informed consent to have their tumor tissue undergo IHC testing as determined by a validated test (tumor tissue may be obtained from archived samples or from a freshly obtained biopsy).

  4. Must have at least 1 measurable target lesion according to RECIST version 1.1.

  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

  6. Participants must have a life expectancy of ≥4 months in the opinion of the Investigator.

  7. Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.

  8. WOCBP must agree to use a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.

  9. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. All male participants must agree to not donate sperm during the study and at least 90 days after the last dose of 177Lu-RAD202, whichever occurs later. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.

  10. Participants with previously treated brain metastases are eligible to participate if:

    1. They are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality [magnetic resonance imaging (MRI) or computed tomography (CT) scan] must be used for each assessment),
    2. Do not require corticosteroids to treat associated neurological symptoms, and
    3. Participants have no history of leptomeningeal disease or spinal cord compression.
    4. Participants with active brain metastases untreated with brain-directed therapy such as radiotherapy, are not eligible.

Exclusion Criteria:

  1. Participants who have any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or nonmelanoma skin cancer. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.

  2. Participants who have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time-point imaging procedures, etc.

  3. Residual toxicity Grade ≥ 2 from previously administered therapy (except for alopecia). Patients with Grade 2 or higher toxicity due to prior treatment may be allowed on a case-by-case basis in discussion with study Sponsor provided it is deemed not to put the participant at a higher risk of treatment-related toxicity or interfere with the integrity of study data, e.g., participants with endocrinopathy on stable replacement therapy

  4. Inadequate organ functions as reflected in laboratory parameters:

    • Creatinine clearance or Body Surface Area (BSA) adjusted Estimated glomerular filtration rate (eGFR) (calculated using any clinically validated formula, preferably Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or measured) < 60 mL/min
    • Platelet count of < 80 x 109/L
    • Absolute neutrophil count (ANC) < 1.5 x 109/L
    • Haemoglobin < 9 g/dL
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN), or > 5 x ULN for participants with known liver metastases
    • Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN
    • For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) ≥ 1.5 or prothrombin time (PT) ≥ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≥1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR < 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
  5. Significant cardiovascular disease including:

    • Unstable angina and/or myocardial infarction within 6 months prior to screening
    • New York Heart Association Class II or greater congestive heart failure
    • Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block)
    • QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec for females and QTcF > 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome
    • Uncontrolled hypertension
    • Known LVEF < 50%. (LVEF may be performed either by echocardiogram or other appropriate imaging modalities such as nuclear cardiac imaging (MUGA) or MRI).
  6. History of uncontrolled allergic reactions and/or have hypersensitivity to anti-HER2 monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients that may induce hypersensitivity

  7. Pregnant or lactating women

  8. Participants who are receiving any other investigational agents

  9. Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD202.

  10. Has had or is scheduled to have major surgery ≤ 28 days prior to the first dose of 177Lu-RAD202. Surgical procedures not considered to put participants at higher risk of AEs and/or interfere with the integrity of study outcome may be allowed on a case-by-case basis in discussion with the Sponsor.

  11. Positive status for human immunodeficiency virus (HIV).

  12. Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.

  13. Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.

  14. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: 177Lu-RAD202

Single-arm, open-label study of 177Lu-RAD202

177Lu-RAD202 administered at treatment doses

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety and tolerability of 177Lu-RAD202
Lasso di tempo: 6 weeks

The properties, incidence, nature and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

6 weeks
Recommended dose(s) of 177Lu-RAD202 for future exploration
Lasso di tempo: 6 weeks

Incidence of dose-limiting toxicities (DLTs) during the first 6 weeks following 177Lu-RAD202 injection cycle of treatment

6 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Preliminary antitumor activity of 177Lu-RAD202
Lasso di tempo: Up to 30 weeks

Objective response rates (ORR) as assessed by RECIST v1.1

Up to 30 weeks
Time Activity Curves (TACs)
Lasso di tempo: 72 hours

Percent of the injected activity vs time for selected organs and tumors

72 hours
Radiation dosimetry of 177Lu-RAD202
Lasso di tempo: 72 hours

Absorbed radiation doses of 177Lu-RAD202tr in critical organs (e.g., kidneys, bone marrow)

72 hours
Pharmacokinetics of 177Lu-RAD202
Lasso di tempo: 72 hours

Half-life of 177Lu-RAD202 in blood

72 hours
Biokinetics of 177Lu-RAD202
Lasso di tempo: 72 hours

Time-integrated activity coefficients of 177Lu-RAD202 in organs and tumor lesions

72 hours

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
To explore the use of SPECT/CT as a measure of preliminary anti-tumor activity of 177Lu-RAD202
Lasso di tempo: Up to 30 weeks

Longitudinal assessments of quantitative tumor uptake of 177Lu-RAD202 using SPECT/CT

Up to 30 weeks
To study the effect of amino acid infusion on 177Lu-RAD202 radiation absorption
Lasso di tempo: Up to 30 weeks

Absorbed radiation doses of 177Lu-RAD202 in critical organs (e.g. kidneys, bone marrow)

Up to 30 weeks
Level of agreement between 177Lu-RAD202 and standard of care imaging
Lasso di tempo: Up to 30 weeks

Standard of care imaging may include but is not limited to 18F-FDG-PET, CT-scan and/or 99mTc-MDP-bone

Up to 30 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 febbraio 2025

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

7 febbraio 2025

Primo inviato che soddisfa i criteri di controllo qualità

7 febbraio 2025

Primo Inserito (Effettivo)

13 febbraio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • RAD202.2022.0002

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .